- Imugene Ltd (ASX: IMU) is raising capital for further immuno-oncology clinical testing
- HER-Vaxx, an anti-cancer vaccine therapy, has been utilised in initial clinical testing on patients with gastric cancer.
- The ASX has granted a halt on trade allowing the company to prepare.
Imugene Ltd (ASX: IMU), a clinical-stage immuno-oncology company treating gastric, breast, ovarian, lung & pancreatic cancers, has arranged a halt on trade approved by the Australian Stock Exchange.
This halt comes about as a result of the company’s desire to raise capital. The halt will allow Imguene to have sufficient preparation time.
HER-Vaxx, the leading Imugene product that capitalises on the body’s ability to create antibodies against disease, has commenced clinical testing on gastric cancer patients.
Two leading antibody medications apply the same method as HER-Vaxx employs, utilising the same receptor. These alternative products possessing annual sales of US $8.2 billion.
About Imugene Ltd (ASX: IMU)
Imugene is a clinical stage immuno-oncology company. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets. HER-Vaxx is an immuno-oncology therapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.